BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5 months in subtypes of refractory soft tissue sarcomas

CAR-T Digest - August 2020

Weekly Digest - November 2025

07 November 2025: BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5 months in subtypes of refractory soft tissue sarcomas

BioAtla shared new Phase 2 data showing that its AXL-targeting ADC, mecbotamab vedotin (Mec-V), delivered a median overall survival of 21.5 months in heavily pretreated soft-tissue sarcoma patients nearly doubling the survival historically seen with approved treatments
Among 44 patients with refractory leiomyosarcoma, liposarcoma, or undifferentiated pleomorphic sarcoma, Mec-V produced encouraging outcomes, including a 73% 12-month OS rate, a 52% disease control rate, and partial responses in two individuals
The therapy leverages BioAtla’s CAB technology to bind AXL only in the acidic tumor microenvironment, allowing targeted payload delivery while reducing toxicity, which contributed to a manageable and predictable safety profile in both monotherapy and combination settings
Patients received Mec-V every two weeks, either alone or with an anti–PD-1 antibody, with combination therapy showing a median OS of 22.9 months compared with 18.4 months for monotherapy
BioAtla emphasized that these results suggest early use of Mec-V may alter long-term outcomes by selectively eliminating AXL-expressing cancer cells that drive resistance, reinforcing the therapy’s promise for patients with few remaining treatment options